Search results for "Normal"

showing 10 items of 2571 documents

Bleomycin, a selective inhibitor of DNA-dependent DNA polymerase from oncogenic RNA viruses.

1972

Abstract Bleomycin, an antibiotic, inhibits the DNA-dependent DNA polymerase from Rauscher murine leukemia virus. Higher concentrations of BLM ∗ are required to inhibit it's RNA-dependent DNA polymerase. These inhibition effects of the non-competitive type are not altered by preincubation of the DNA with BLM. Under comparable conditions neither the DNA-dependent DNA polymerase activity from E. coli and mouse liver nor the DNA-dependent RNA polymerase activity from mouse lymphoma cells are affected by BLM.

congenital hereditary and neonatal diseases and abnormalitiesTime FactorsLymphomaDNA polymeraseHepatitis B virus DNA polymeraseUracil NucleotidesDNA polymerase IIBiophysicsRNA-dependent RNA polymeraseCytosine NucleotidesTritiumBiochemistryRauscher VirusCell LineBleomycinMiceEscherichia coliAnimalsMolecular BiologyPolymeraseDNA clampAntibiotics Antineoplasticbiologyurogenital systemnutritional and metabolic diseasesCell BiologyDNAMolecular biologyReverse transcriptaseKineticsReal-time polymerase chain reactionLiverDNA Nucleotidyltransferasesbiology.proteinRNABiochemical and biophysical research communications
researchProduct

Bleomycin: Action on growth of oncogenic RNA viruses and on cell transformation

1975

Bleomycin (BLM) inhibits cell proliferation of noninfected chick embryo fibroblasts by blocking their DNA synthesis selectively. Chick embryo fibroblasts have beentransformed by Schmidt-Ruppin D strain of Rous Sarcoma Virus. Transformation has been determined by a focus assay. Foci formation is strongly reduced by BLM. Virus replication is inhibited by BLM in growing and confluent monolayer cells. This result might be explained by the observation that this drug reduces proliferation of growing and of confluent monolayer cells very sensitively. During the first 24 hours after infection the BLM inhibitory effect is more pronounced than in the case of BLM-application during the period 24--48 h…

congenital hereditary and neonatal diseases and abnormalitiesTime Factorsanimal structuresTranscription GeneticCell divisionCellChick EmbryoBiologyVirus ReplicationVirusBleomycinTranscription (biology)VirologymedicineAnimalsRNA VirusesCells CulturedRous sarcoma virusurogenital systemCell growthnutritional and metabolic diseasesRNADNAGeneral MedicineFibroblastsbiology.organism_classificationVirologyMolecular biologyCell Transformation Neoplasticmedicine.anatomical_structureAvian Sarcoma VirusesViral replicationembryonic structuresRNARNA ViralArchives of Virology
researchProduct

Prader Willi Syndrome : Saliva quantification and culture in 10 patients

2008

Prader Willi Syndrome (PWS) is a relatively rare neurogenetic illness. It is of interest to dentists for its clinical characteristics. The aim of this study was to evaluate the amount of saliva and the presence of Streptococcus mutans (S mutans) in patients with this syndrome. We measured saliva stimulated by chewing paraffin tablets for 5 minutes, and cultured saliva samples in order to determine the colony-forming units (CFUs) of S mutans. The study was conducted in a group of 10 children with PWS at the Hospital Sant Joan de Déu, Barcelona. Results showed that patients with PWS had lower saliva secretion than considered normal for a standard population and most cultures presented a high …

congenital hereditary and neonatal diseases and abnormalitiesUNESCO::CIENCIAS MÉDICASnutritional and metabolic diseases:CIENCIAS MÉDICAS [UNESCO]nervous system diseases
researchProduct

WRN protects against topo I but not topo II inhibitors by preventing DNA break formation

2008

The Werner syndrome helicase/3′-exonuclease (WRN) is a major component of the DNA repair and replication machinery. To analyze whether WRN is involved in the repair of topoisomerase-induced DNA damage we utilized U2-OS cells, in which WRN is stably down-regulated (wrn-kd), and the corresponding wild-type cells (wrn-wt). We show that cells not expressing WRN are hypersensitive to the toxic effect of the topoisomerase I inhibitor topotecan, but not to the topoisomerase II inhibitor etoposide. This was shown by mass survival assays, colony formation and induction of apoptosis. Upon topotecan treatment WRN deficient cells showed enhanced DNA replication inhibition and S-phase arrest, whereas af…

congenital hereditary and neonatal diseases and abnormalitiesWerner Syndrome HelicaseDNA RepairCell SurvivalDNA damageDNA repairBlotting WesternApoptosisBone NeoplasmsBiologyTopoisomerase-I InhibitorBiochemistryArticleWerner Syndrome HelicaseColony-Forming Units AssayHistonesTumor Cells CulturedmedicineHumansTopoisomerase II InhibitorsEnzyme InhibitorsRNA Small InterferingeducationMolecular BiologyEtoposideOsteosarcomaeducation.field_of_studyRecQ HelicasesTopoisomeraseCell CycleDNA Breaksnutritional and metabolic diseasesCell BiologyAntineoplastic Agents PhytogenicMolecular biologyDNA Topoisomerases Type IIExodeoxyribonucleasesBromodeoxyuridineDNA Topoisomerases Type IDNA Replication InhibitionCancer researchbiology.proteinTopoisomerase I InhibitorsTopoisomerase-II InhibitorTopotecanCamptothecinmedicine.drugDNA Repair
researchProduct

Activity and kinetics of DNA dependent DNA and RNA polymerases n xeroderma pigmentosum and in normal human skin.

1971

1. DNA dependent DNA polymerase (E.C.2.7.7.7) was prepared from human normal and from Xeroderma pigmentosum skin. 2. DNA polymerase from normal skin has the same Michaelis constant with native and denatured DNA as templateKm= 120 ± 11 µg DNA/ml, with differing maximum reaction velocities. 3. The enzyme from Xeroderma pigmentosum has the same Michaelis constant for denatured DNA as the enzyme from normal skin, but with native DNA as template, theKmvalue is lower (97.2 ± 9.8). The maximum reaction velocities of the Xeroderma pigmentosum enzyme with native resp. denatured DNA as template are the same. 4. DNA dependent RNA polymerases (E.C.2.7.7.6) from normal and Xeroderma pigmentosum skin wer…

congenital hereditary and neonatal diseases and abnormalitiesXeroderma pigmentosumDNA polymeraseDNA polymerase IIDermatologyTritiumEndonucleasechemistry.chemical_compoundmedicineHumansskin and connective tissue diseasesPolymeraseSkinCarbon IsotopesXeroderma PigmentosumDNA clampintegumentary systembiologynutritional and metabolic diseasesRNA NucleotidyltransferasesGeneral MedicineDNAClinical Enzyme Testsmedicine.diseaseMolecular biologyEnzyme ActivationchemistryDNA Nucleotidyltransferasesbiology.proteinPrimer (molecular biology)DNAArchiv fur dermatologische Forschung
researchProduct

ChemInform Abstract: Tuning the Band Gap of PbCrO4Through High-Pressure: Evidence of Wide-to-Narrow Semiconductor Transitions.

2014

Commercial polycrystalline and cleaved platelets from natural PbCrO4 are studied in a diamond anvil cell at ≤ 21 GPa.

congenital hereditary and neonatal diseases and abnormalitiesbusiness.industryBand gapChemistryA diamondmacromolecular substancesGeneral MedicineSemiconductorstomatognathic systemhemic and lymphatic diseasesHigh pressureparasitic diseasesOptoelectronicsCrystallitebusinessChemInform
researchProduct

Role of Adenosine Receptors in Rare Neurodegenerative Diseases with Motor Symptoms

2021

: The approval of istradefylline, an adenosine 2A receptor (A2AR) antagonist, as an addon treatment in adult patients with Parkinson’s disease by the Food and Drug Administration (FDA) and European Medicines Agency (EMA), is the latest proof of the importance of the adenosinergic system in the nervous system. Adenosine is an endogenous purine nucleoside with a role as a modulator of both neurotransmission and the inflammatory response. As such, the expression pattern of the 4 adenosine receptors (A1R, A2AR, A2BR and A3R) and the extracellular adenosine levels have attracted great interest in the pathogenesis and possible treatment of rare neurodegenerative diseases with motor symptoms. The…

congenital hereditary and neonatal diseases and abnormalitiesbusiness.industryNeurodegenerationNeurodegenerative DiseasesCell BiologyGeneral MedicineAdenosinergicIstradefyllinemedicine.diseaseBioinformaticsBiochemistryAdenosine receptorAdenosinechemistry.chemical_compoundchemistrymedicineSpinocerebellar ataxiaAmyotrophic lateral sclerosisbusinessMolecular BiologyMachado–Joseph diseasemedicine.drugCurrent Protein & Peptide Science
researchProduct

Additional file 1 of Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional …

2020

Additional file 1: Figure S1. Distribution of the number of echocardiograms performed per patient. Number of echocardiograms per patient ranged from 2 (minimum inclusion criteria) to 9 (patients with all the per protocol pre-specified echocardiograms).

congenital hereditary and neonatal diseases and abnormalitiescardiovascular systemcardiovascular diseasescirculatory and respiratory physiology
researchProduct

Substrate specificity overlap and interaction between Adrenoleukodystrophy protein (ALDP/ABCD1) and Adrenoleukodystrophy-related protein (ALDRP/ABCD2)

2011

X-linked adrenoleukodystrophy (X-ALD) is a neurodegenerative disorder caused by mutations in the ABCD1 gene, which encodes a peroxisomal member of the ATP-binding cassette (ABC) transporter subfamily D called ALDP. ALDP is supposed to function as a homodimer allowing the entry of CoA-esters of very-long chain fatty acids (VLCFA) into the peroxisome, the unique site of their β-oxidation. ALDP deficiency can be corrected by overexpression of ALDRP, its closest homolog. However, the exact nature of the substrates transported by ALDRP and its relationships with ALDP still remain unclear. To gain insight into the function of ALDRP, we used cell models allowing the induction in a dose-dependent m…

congenital hereditary and neonatal diseases and abnormalitiesendocrine system diseasesATP-binding cassette transportermembrane proteinsBiologyATP Binding Cassette Transporter Subfamily DBiochemistry03 medical and health sciences0302 clinical medicineabc transporterCell Line TumormedicineAnimals[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Molecular BiologyBeta oxidationfatty acid oxidation030304 developmental biologychemistry.chemical_classification0303 health sciencesadrenoleukodystrophyabc transporter;fatty acid;fatty acid oxidation;membrane proteins;peroxisomes;adrenoleukodystrophyFatty AcidsNeurosciencesWild typeFatty acidnutritional and metabolic diseasesperoxisomesCell BiologyPeroxisomemedicine.diseaseLipidsRatschemistryMembrane proteinBiochemistry[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Neurons and CognitionATP-Binding Cassette TransportersAdrenoleukodystrophy[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]fatty acidOxidation-Reduction030217 neurology & neurosurgeryPolyunsaturated fatty acid
researchProduct

ANKRD26-RET - A novel gene fusion involving RET in papillary thyroid carcinoma

2018

Abstract Background Rearrangements of RET are drivers of oncogenesis, traceable in different cancer types as papillary thyroid carcinoma (PTC), non-small cell lung cancer, colorectal or breast cancer. Anchored multiplex PCR based next-generation sequencing (NGS) can detect RET rearrangements involving previously unknown partner genes. Methods A sample of PTC underwent NGS, following detection of RET rearrangement by fluorescence in situ hybridization. Expression analysis of ANKRD26 and RET was performed for the tumor harboring ANKRD26-RET, for corresponding normal thyroid tissue and PTC tumors with representative genetic alterations (BRAFV600E, CCDC6-RET), complemented by a comparative sear…

congenital hereditary and neonatal diseases and abnormalitiesendocrine systemCancer Researchendocrine system diseasesBiologymedicine.disease_causeMetastasisThyroid carcinoma03 medical and health sciences0302 clinical medicineGeneticsmedicineHumansThyroid NeoplasmsneoplasmsMolecular BiologyGenemedicine.diagnostic_testProto-Oncogene Proteins c-retThyroidHigh-Throughput Nucleotide SequencingCancermedicine.diseaseSurvival Analysismedicine.anatomical_structureThyroid Cancer Papillary030220 oncology & carcinogenesisCancer researchIntercellular Signaling Peptides and ProteinsGene FusionCarcinogenesisTyrosine kinaseFluorescence in situ hybridizationCancer Genetics
researchProduct